We are live on
!
Find out more
PGP
Prescott General Partners Portfolio holdings
AUM
$1.37B
1-Year Est. Return
23.81%
This Fund
S&P 500
This Quarter
Est. Return
-2.82%
1 Year Est. Return
+23.81%
3 Year Est. Return
+67.15%
5 Year Est. Return
+9.62%
10 Year Est. Return
+525.75%
AUM
$1.53B
AUM Growth
-$184M
(-11%)
Cap. Flow
-$122M
Cap. Flow
% of AUM
-7.99%
Top 10 Holdings %
Top 10 Hldgs %
99.58%
Holding
12
New
1
Increased
–
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lineage Cell Therapeutics
LCTX
|
+$6.01M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOCK
LifeLock, Inc.
LOCK
|
+$128M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 40.42% |
| 2 | Industrials | 32.62% |
| 3 | Consumer Discretionary | 8.62% |
| 4 | Communication Services | 6.79% |
| 5 | Technology | 6.37% |
Similar funds
DC
FC
QF
KRS
AF
PP
CRM
SOS
Prescott General Partners's Q1 2017 Portfolio in Review
As of Q1 2017, Prescott General Partners held 12 positions worth $1.53B, down 11% from $1.72B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Prescott General Partners withdrew a net $122M in Q1 2017, closing 1 position. Its most notable exit was LifeLock, Inc., an estimated $128M position sold in full.
By sector, the portfolio is most concentrated in Financials at 40% of assets, up from 40% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Prescott General Partners opened a new position in Lineage Cell Therapeutics worth $6.39M.
- Prescott General Partners's largest Q1 2017 buy was Lineage Cell Therapeutics: 2,116,666 shares worth $6.39M.
- Prescott General Partners fully exited LifeLock, Inc. in Q1 2017, selling an estimated $128M.
- Prescott General Partners's ten largest holdings make up 100% of its $1.53B portfolio in Q1 2017.
- Prescott General Partners opened 1 new position and closed 1 in Q1 2017.
- Prescott General Partners's portfolio value fell 11% quarter-over-quarter to $1.53B.
Based on Prescott General Partners's 13F filing for Q1 2017, filed 15 May 2017.